A novel oral therapy for moderate-to-severe psoriasis.
I Derm Pharma is advancing IDRM-7, a novel non-JAK small molecule that simultaneously suppresses the psoriatic disease program and restores the healthy keratinocyte program - with biologic-level efficacy in oral form.
¹ Preclinical, humanized psoriasis xenograft model.
We treat psoriasis differently
EffectivelySafelyOrallysingle dose
With a Novel Mode of Action
We are developing a next-generation oral therapy for Psoriasis.
Targeted oral therapies are the next growth wave in a validated, multi-billion-dollar market.
The psoriasis treatment landscape is shifting towards convenient targeted oral therapy
Biologics dominate
TNF-α, IL-17 and IL-23 biologics set the efficacy standard today.
Biosimilars are eroding
Lower-cost copies are pressuring originator pricing and revenues.
Targeted oral therapies
The next growth wave: oral, selective, chronic-use friendly options.
IDRM-7A novel oral non-JAK small molecule for moderate-to-severe psoriasis.
78% disease recovery in humanized psoriasis mouse model.
A novel non-JAK mechanism - no direct competitor.
Encouraging preclinical safety with wide therapeutic window.
Composition-of-matter protection with long exclusivity.
>50% oral bioavailability with minimal first-pass metabolism.
Other Inflammatory and Immune-Mediated Conditions
Graft Recovery
In human psoriasis xenograft model
2 weeks, BID
Strong oral efficacy in a humanized psoriasis model
IDRM-7 matched the approved oral TYK2 inhibitor Sotyktu® (deucravacitinib) through a differentiated mechanism.
- Efficacy comparable to Sotyktu® across disease axes (Baker score, proliferation, cytokine & antimicrobial peptides)
- No statistically significant difference between treatments
- Significant improvement vs Vehicle
Novel dual-action oral mechanism of action
IDRM-7 suppresses inflammation and restores healthy skin cells
SUPPRESSES psoriatic-disease program
- Pro-inflammatory AMPs
- Type I IFN / ISG cassette
- Th17 amplifier loop
RESTORES healthy keratinocyte program
- Normal cell cycle control
- Antioxidant response
- Epidermal barrier/differentiation program
IDRM-7 engages key therapeutic pathways without triggering cellular stress response
A unique position in the psoriasis landscape
Anti-IL-17, Anti-IL-23/12, Anti-TNF, Anti-IL-36R, TYK2 inhibitors, PDE4 inhibitors, Anti-IL-23 receptor, Methotrexate, Cyclosporine
PDE4 inhibitors, JAK inhibitor, Corticosteroids
AhR agonist, Vit D receptor activator, Retinoid
IDRM-7 is the only oral therapy that combines suppression with active restoration of healthy skin cells.
A safety and oral profile suited to chronic use.
Across 60+ toxicological endpoints (Derek Nexus)
Well tolerated in rats; 550 mg/kg repeated dose also well tolerated
At 0.1 mM - no integrated stress response
Preclinical data. Rat studies.
A timely opportunity in a growing market.
Suppresses inflammation and restores healthy tissue function.
78% lesion recovery in a humanized psoriasis model.
Encouraging preliminary preclinical safety profile.
Oral dosing expected to improve adherence versus injectable biologics.
Composition-of-matter patent with long-term exclusivity.
Mechanism potentially applicable to other immune-mediated conditions.
Experienced leaders with deep drug-development expertise.
Partnering & investment opportunities available.
A unique opportunity in a validated, growing market - biologic-level efficacy, oral convenience, and a novel mechanism.